Patents by Inventor Mitchell H. Keylor

Mitchell H. Keylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20230406844
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: October 27, 2021
    Publication date: December 21, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Peter H. Fuller, Anmol Gulati, Solomon D. Kattar, Mitchell H. Keylor, Kaila A. Margrey, Xin Yan
  • 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20230303540
    Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
    Type: Application
    Filed: September 1, 2021
    Publication date: September 28, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: John J. Acton, III, Ryan Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon Kattar, Mitchell H. Keylor, Derun Li, Kaila A. Margrey, Gregori J. Morriello, Xin Yan
  • N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20230023066
    Abstract: The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
    Type: Application
    Filed: October 20, 2020
    Publication date: January 26, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mitchell H. Keylor, Michael J. Ardolino, Ryan W. Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon D. Kattar, Kaila A. Margrey, Gregori J. Morriello, Santhosh F. Neelamkavil, Xin Yan, Elsie C. Yu, Cayetana Carmela Zarate Saez
  • 1-PYRAZOLYL, 5-, 6- DISUBSTITUTED INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF
    Publication number: 20220259188
    Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
    Type: Application
    Filed: June 1, 2020
    Publication date: August 18, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Hua Zhou, John J. Acton, III, Michael J. Ardolino, Yi-Heng Chen, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, William P. Kaplan, Solomon D. Kattar, Mitchell H. Keylor, Derun Li, Kaitlyn Marie Logan, Min Lu, Gregori J. Morriello, Santhosh F. Neelamkavil, Barbara Pio, Nunzio Sciammetta, Vladimir Simov, Jing Su, Luis Torres, Xin Yan